What are the Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus?
According to the American College of Physicians, Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus are guided by a patient's risk for hypoglycemia, comorbidities, life expectancy, and goals of therapy established by the patient and the healthcare professional. Generally, the hemoglobin A1c target should be less than 7.0%, but individualized targets may be lower or higher depending on the patient's circumstances. Lower targets are typically reserved for younger patients without comorbidities and higher targets may be appropriate for patients at risk of hypoglycemia and those with limited life expectancy or significant comorbidities.